Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Syndax Pharmaceuticals Inc. (SNDX)
:SNDX
RESEARCH TOOLSreports
Holding SNDX?
Track your performance easily
Earnings Data
Report Date
Mar 05, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
-0.85Last Year’s EPS
-1Same Quarter Last Year
Strong Buy
Based on 13 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Nov 05, 2018
|% Change Since: -33.57%
|Next Earnings Date:Aug 07, 2018
Earnings Call Sentiment|Positive
The earnings call reflected a strong positive trajectory for Syndax, highlighted by the FDA approval of Niktimvo and significant financial backing through the Royalty Pharma agreement. While the delay in the PDUFA date for Revumenib was a minor setback, the overall sentiment remains optimistic with multiple anticipated approvals and a robust financial position.Company Guidance
In the third quarter of 2024, Syndax Pharmaceuticals delivered significant achievements, including the FDA approval for Niktimvo, marking a pivotal transition to an integrated commercial stage company. A $350 million royalty agreement with Royalty Pharma bolstered their financial position, enabling funding through profitability. Key milestones included the AGAVE-201 trial results publication in the New England Journal of Medicine and Niktimvo's inclusion in the NCCN guidelines, underscoring its critical role in chronic GVHD treatment. Syndax anticipates FDA approval for Revumenib, with a PDUFA date of December 26, 2024, and aims to expand its impact in acute leukemia through forthcoming pivotal data from the AUGMENT-101 trial, targeting a combined addressable market of up to $2 billion in the U.S.FDA Approval of Niktimvo
Achieved FDA approval for Niktimvo, the first CSF1R antibody for chronic GVHD, marking a significant milestone in the company's transition to a commercial stage.
Royalty Agreement with Royalty Pharma
Secured a $350 million royalty agreement for Niktimvo, enhancing the company's balance sheet and funding through profitability.
Revumenib Anticipated FDA Approval
Expecting FDA approval for Revumenib in the current quarter, with positive indications for its role in treating KMT2A rearranged acute leukemia.
Strong Financial Position
With $399.6 million in cash and an additional $350 million from the royalty agreement, the company is well-positioned to reach profitability.
Positive Data from Clinical Trials
Updated data from AUGMENT-101 and SAVE trials show promising results for Revumenib, with high overall response rates and potential best-in-class status.
---
SNDX Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
SNDX Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 05, 2024 | $19.69 | $21.35 | +8.43% |
| Aug 01, 2024 | $22.00 | $21.04 | -4.36% |
| May 08, 2024 | $23.18 | $22.38 | -3.45% |
| Feb 27, 2024 | $24.41 | $23.88 | -2.17% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Syndax Pharmaceuticals Inc. (SNDX) report earnings?
Syndax Pharmaceuticals Inc. (SNDX) is schdueled to report earning on Mar 05, 2025, TBA Not Confirmed.
What is Syndax Pharmaceuticals Inc. (SNDX) earnings time?
Syndax Pharmaceuticals Inc. (SNDX) earnings time is at Mar 05, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is SNDX EPS forecast?
SNDX EPS forecast for the fiscal quarter 2024 (Q4) is -0.85.
---